Process Chemistry in the Pharmaceutical Industry. (1999)

• Record Type: Book
• Further Information: Note: Editor, Kumar Gadamasetti.
• Editors: Gadamasetti, Kumar
• Contents: Cover; Half Title; Title Page; Copyright Page; Dedication; CONTENTS; FOREWORD 1; FOREWORD 2; THE CHALLENGES OF PROCESS R PREFACE; ACKNOWLEDGMENTS; CONTRIBUTORS; OVERVIEW; 1: Process Chemistry in the Pharmaceutical Industry: An Overview; Introduction; Big picture; Green chemistry; Prescription Pharmaceutical Drugs; Process Chemistry; Special Topics; Future Trends; References; STRATEGY; 2: Process Research and Development Strategy for Accelerated Projects; Time-based Competition; Portfolio Management; Aztreonam; Fosinopril; Post-merger Integration Paclitaxel Development and Process IntroductionAcknowledgments; References; CASE STUDIES; 3: A Practical Synthesis of Ifetroban Sodium; Acknowledgments; References; 4: Synthesis of 5-Lipoxygenase Inhibitors; Introduction; References; 5: Chemistry of Vitamin D: A Challenging Field for Process Research; Synthesis of Ro 23-8525; Syntheses of the 16-Vitamin D Analogs 7 and 8; Concluding Remarks; References; 6: A Highly Optimized and Concise Large Scale Synthesis of a Purine Bronchodilator; Introduction: Pharmacological Concept & Identification of Target Molecule Starting Point for Process R&D: The Medicinal Chemistry RouteInitial Development Leading to Identification of a Viable Synthetic Route; Design of Final In-House Process & Scale-Up; Characteristic Process Features & Summary of Developmental Conclusions; Concluding Statements; Acknowledgement; References; 7: Ontazolast: The Evolution of a Process; INTRODUCTION; BACKGROUND AND SYNTHETIC STRATEGY; FIRST SYNTHESIS OF ONTAZOLAST VIA RESOLUTION; SECOND SYNTHESIS OF ONTAZOLAST BY REDUCTION OF A CHIRAL IMINE; ALTERNATIVE ASYMMETRIC SYNTHESIS OF (S)-2 BY DIASTEREOSELECTIVE ALKYLATION; REFERENCES 8: Dilevalol Hydrochloride: Development of a Commercial Process1. Background; 2. Introduction; 3. Early conside rations in Selecting a Synthesis Route for Further Development; 4. Synthesis of Initial Supplies of Dilevalol for Cardiovascular Therapy Team Programs; 5. Selecting the NDA Process and Reducing the Cost-Of-Goods; 6. Development of the New NDA Process to a Commercial Scale; 7. Ongoing Process Development and Alternative Routes to dilevalol; 8. Withdrawal of Dilevalol Hydrochloride from the Market; 9. Acknowledgments; 10. Bibliography 9: Design and Development of Practical Syntheses of LY228729, a Potent 5HT1a Receptor AgonistIntroduction; Original Synthetic Route for LY228729; Second Generation Synthetic Route. Diastereoselective Epoxidation; Tryptophan Route; Comparison of Synthetic Routes; Acknowledgments; References; 10: Process Research and Development of CGS 19755, an NMDA Antagonist; Introduction; Research Synthesis; Retrosynthetic Approach for Development; Batch 0/1: Speed in synthesis; Batches 2/3: Rapid Development and Scale-up; Batches 4, 5, 6 : Final Process Selection and Optimization; Summary; Acknowledgments
• Publisher Details: Boca Raton, FL : CRC Press
• Publication Date: 1999
• Extent: 1 online resource
• Subjects: 615/.19; Drugs -- Design; Pharmaceutical chemistry; Chemical engineering; Chemistry, Technical; Chemical engineering; Chemistry, Technical; Drugs -- Design; Pharmaceutical chemistry; Electronic books
• Languages: English
• ISBNs: 9781482276091; 1482276097
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.